Niagen Brings Prescription NAD+ Injections Directly to Your Home via Telehealth

Niagen Bioscience has introduced Niagen Plus, a telehealth platform that delivers prescription-only NAD+ subcutaneous injection kits directly to patients' homes across the US. This marks the company's first direct-to-consumer model, expanding beyond its existing clinic-based intravenous offerings and representing a structural shift in how longevity-focused therapeutics reach patients.

The platform works by pairing eligible patients with licensed clinicians via remote consultation. If approved, patients receive a kit from a 503A compounding pharmacy containing a 500 mg vial of pharmaceutical-grade nicotinamide riboside chloride powder, bacteriostatic water, syringes, and QR-code-linked instructions. Clinicians prescribe either a 50 mg or 100 mg dose based on individual assessment. A cited clinical safety trial found the injectable formulation was generally well tolerated with no significant adverse effects at these doses.

The core molecule — nicotinamide riboside — is the same ingredient found in Niagen's widely sold Tru Niagen oral supplement. The injectable route is intended to bypass gut metabolism, theoretically enabling more direct systemic delivery and higher bioavailability. By wrapping this in a prescription framework with clinician oversight, Niagen is repositioning itself from the wellness supplement market toward something resembling a formal medical intervention.

This launch reflects a broader trend in longevity medicine: established molecules being repackaged within healthcare infrastructure to gain regulatory legitimacy and consumer trust. Telehealth here functions as a distribution layer, not merely a convenience feature, enabling scalable access while maintaining clinical language and oversight protocols.

However, important caveats remain. NAD+ is one of the most commercially active and scientifically contested pathways in longevity research. While its biology is well characterized — supporting mitochondrial function and DNA repair — evidence linking NAD+ supplementation or injection to meaningful clinical outcomes in humans remains under active investigation. The delivery model is maturing faster than the evidentiary base, and health-conscious consumers should weigh access convenience against the still-incomplete clinical picture.